Golden Helix Received ISO 13485:2016 Certification

· Andreas Scherer · About Golden Helix

This month, we are excited to announce that we have received the certification for ISO 13485:2016 from TÜV SÜD. ISO 13485:2016 is an international standard that specifies requirements for a quality management system (QMS) for organizations involved in the design, development, production, and servicing of medical devices. It is specifically tailored to the medical device industry and is recognized globally as a benchmark for ensuring the quality and safety of medical devices.

In order to be certified, an organization has to maintain a quality management system, demonstrate sufficient risk management, and show consistent tracking of customer satisfaction and safety in the market as well as demonstrate continued improvement efforts on the product and system level.

We are very pleased to receive ISO 13485:2016 certification. It’s a testament to our efforts of continuous quality improvements, including our software development processes, customer success and support processes, and all other operational processes within our company. ISO 13485:2016 is designed to objectively document that we are holding ourselves to the highest quality standards as we are providing innovative solutions to hospitals, testing labs, and research institutions globally.

ISO 13485:2016 is crucial in the context of In Vitro Diagnostic Regulation (IVDR) because it ensures the safety and effectiveness of in vitro diagnostic devices (IVDs). It establishes quality management system requirements for IVD manufacturers, aligning with the IVDR’s regulatory framework. ISO 13485:2016 emphasizes risk management, documentation, traceability, competency, and continual improvement, all vital aspects of IVDR compliance.

In this context, it is very timely to note that the FDA issued the Quality Management System Regulation (QMSR) Final Rule on January 31, 2024. The QMSR rule emphasizes risk management activities and risk-based decision-making and aims to reduce regulatory burdens on device manufacturers and importers by harmonizing domestic and international requirements, specifically through the adoption of ISO 13485. The rule amends the current good manufacturing practice requirements of the Quality System regulation in 21 CFR 820.

We are proud to be recognized for our efforts and will continue to strive for excellence in precision medicine.

Leave a comment

Andreas Scherer

About Andreas Scherer

Dr. Andreas Scherer is CEO of Golden Helix. The company has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over a decade. Its innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from next-generation sequencing. With its solutions, hundreds of the world’s hospitals and testing labs are able to harness the full potential of genomics to identify the cause of disease, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in thousands of peer-reviewed publications. Golden Helix is also on the Inc 5000 list of the fastest-growing private companies in the US. He is also Managing Partner of Salto Partners, Inc, a management consulting firm headquartered in Nevada.  He has extensive experience successfully managing growth as well as orchestrating complex turnaround situations. His company, Salto Partners, advises on business strategy, financing, sales, and operations. Clients are operating in the high-tech and life sciences space. Dr. Scherer holds a Ph.D. in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is author and co- author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, “Be Fast Or Be Gone”, is a prizewinner in the 2012 Eric Hoffer Book Awards competition, and has been named a finalist in the 2012 Next Generation Indie Book Awards! 

View all posts by Andreas Scherer →